Assembly Biosciences is a clinical-stage company developing ABI-6250, a once-daily pill that blocks a liver transporter, for hepatitis delta and cholestatic liver diseases; it also shares in herpes drugs licensed to Gilead. None is approved.
Assembly's case now rests on ABI-6250, an oral blocker of NTCP, the transporter hepatitis delta virus uses to enter liver cells, and it has no patient data yet. Assembly plans a Phase 2 in chronic hepatitis delta by the end of 2026 and a basket study in primary biliary cholangitis and primary sclerosing cholangitis in Q1 2027. Its herpes programs are licensed to Gilead, and counting a $75 million Gilead fee due in Q4 2026, Assembly expects to fund operations into 2029.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: ABI-6250 Phase 2 in hepatitis delta starts by year-end
Do both ABI-6250 Phase 2 studies start on schedule with designs that can show an effect in patients?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Assembly Bio plans Phase 2 trials of ABI-6250 in hepatitis delta by year-end and in PBC and PSC in Q1 2027, while Gilead takes GS-1179 into Phase 2 for genital herpes
ABI-6250's NTCP-targeting mechanism enters Phase 2 in HDV and cholestatic diseases; thesis hinges on whether early efficacy signals emerge across these indications
Gilead's $35M HPI license validates Assembly's herpes franchise as ABI-4334's rejection forces a partnership reset and concentrates the thesis
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Infectious diseases, Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
7 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.